Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3972497 | 0.97 | LMNA (0.48) | LMNAALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL3964955 | 0.97 | LMNA (0.48) | LMNAALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL2687485 | 0.94 | LMNA (0.50) | LMNAALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL10662960 | 0.87 | ALDH1A1 (0.50) | LMNAALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL14808198 | 0.86 | LMNA (0.65) | LMNAALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL10811553 | 0.86 | ALDH1A1 (0.54) | LMNAALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL6011899 | 0.84 | LMNA (0.42) | LMNAALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL28082913 | 0.84 | ALDH1A1 (0.52) | LMNAALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL17526728 | 0.84 | ALDH1A1 (0.46) | LMNAALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL17526518 | 0.84 | ALDH1A1 (0.46) | LMNAALDH1A1TDP1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023166198-A1 | EYE MAKEUP COMPOSITION BASED ON A VOLATILE MIXTURE OF ALKANES | BIOSYNTHIS (FR) | 2023-09-07 | — | — | WO | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| EP-2360158-A1 | Pyrazole derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-08-24 | — | — | EP | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | disclosed |
| US-4371525-A | Silyl-benzimidazole-2-carbamic acid esters and their use as fungicides | BASF AKTIENGESELLSCHAFT (DE) | 1983-02-01 | — | — | US | disclosed |
| EP-0029993-B1 | SILYL-BENZIMIDAZOLE-CARBAMIC ACID ESTERS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES | BASF Aktiengesellschaft (DE) | 1982-10-13 | — | — | EP | disclosed |
| EP-0029993-A1 | Silyl-benzimidazole-carbamic acid esters, process for their preparation and their use as fungicides | BASF Aktiengesellschaft (DE) | 1981-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | LMNA 4724/4885ALDH1A1 1435/4885TDP1 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.